Agillic, specialists in customer lifecycle management, today announced that ELRO, a leading utility and network operator in Denmark offering mobile, fixed line, VoIP and broadband services is to deploy Agillic’s CLM solution.
ELRO’s decision to invest in Agillic’s CLM was driven by its new WiMax offering which has the potential to replace cable and DSL services by providing universal internet access anywhere you go. Just as cell phones have done to phone access. ELRO’s WiMax service will allow its customers to automatically connect their computers to the closest WiMax antenna…
Danish-Swedish researchers in the biotech company Zymenex have developed Metazym, a lysosomal enzyme, for the treatment of the lethal disease Metachromatic Leukodystrophy (MLD). The Danish Medicines Agency and the Independent Ethics Committee approved a Phase I/II clinical trial, which is now being performed in Denmark on patients from around Europe…
Offering fixed, mobile, internet and in the future IPTV services, the challenge facing this company is the flexibility required to effectively cross and upsell its extensive product portfolio. The complexity of the underlying systems is proving to be a barrier to customer communications.
With Agillic’s SOA architecture it is easily able to integrate with any existing IT system to collate a single view of the customer and thereby create a seamless customer experience. Full digital marketing programmes will then be devised to match the needs of the customer with the right products to create the same high level of loyalty it currently enjoys from its energy customers amongst its telecommunication customers.
Sunstone Technology Ventures has invested in Prezi Inc., a developer of online presentation services on www.prezi.com. The Prezi platform utilizes a Zoomable User Interface to give a distinctly different presentation experience. Users can create presentations online directly in the browser or use an off-line editor for editing. Likewise “Prezis” can be presented in both on-line and offline mode.
Symphogen A/S announced today that it has entered into a global strategic collaboration with Genentech, Inc. for antibody therapeutics against three undisclosed infectious disease targets. In this collaboration, Symphogen will apply its proprietary Symplex™ antibody discovery technology platform to identify novel infectious disease drug candidates. Furthermore, Genentech will gain access to Symphogen’s Sympress™ technology to produce recombinant polyclonal antibodies.